Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Therapy related coagulopathies

Danaparoid (Orgaran)

Reviewer: Jeremy Parsons, M.D. (see Reviewers page)
Revised: 12 June 2012, last major update June 2012
Copyright: (c) 2002-2012, PathologyOutlines.com, Inc.


● Approved to prevent deep venous thromboses
● Also an alternative to heparin for patients with heparin induced thrombocytopenia (Crit Care 2007;11:R102)
● Use is decreasing due to newer anticoagulants
● Composed of low molecular weight glycosaminoglycans (mixture of heparan sulfate, dermatan sulfate and chondroitin sulfate) that primarily inhibit factor Xa, factor IIa to a much lesser extent

Clinical features

● Similar to low molecular weight heparin in having a more predictable anticoagulant effect, with less need for laboratory monitoring
● Monitor, if desired, by measuring inhibitor of factor Xa using standard curve; draw 6 hours after subcutaneous injection; PT and PTT are unaffected
● Therapeutic levels to treat DVT are 0.5-0.8 anti-factor Xa units/ml, lower for DVT prophylaxis
● Long half-life, is prolonged with renal failure
● No reversal agent is known, but incomplete reversal is shown with protamine sulfate
● Not marketed in the US since 2004, still available in some countries.

End of Coagulation > Therapy related coagulopathies > Danaparoid (Orgaran)

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).